| Trial | Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry (PERI-DYS)
ClinicalTrials.gov Identifier: NCT03110432 |
| Aim | Registry study |
| Study design | Prospective observational registry. Patients will receive either standard lipid lowering therapy (statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids and any combinations of these agents), or a PCSK9 inhibitor. The duration of the study is 3 years. |
| Patients | 2000 patients with dyslipidemia with very high cardiovascular risk who principally meet the Gemeinsamer Bundesausschuss (G-BA) stipulations for PCSK9 use, and are treated by office-based cardiologists or in lipid ambulances. |
| Primary outcome | LDL cholesterol goal achievement < 70 mg/dl at 3 years |
| Key results | Ongoing |
| Safety | |
| Author conclusion | |
| Publication | |
| Link | https://clinicaltrials.gov/ct2/show/NCT03110432 |
News
VICTORION-INITIATE supports early inclisiran treatment in ASCVDLIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVDUS patients missing out on bempedoic acidEvolocumab benefits in patients with autoimmune and inflammatory diseasesCLEAR Outcomes confirms bempedoic acid benefits for recurrent CV eventsPCSK9i access remains challenging in USA
